Hemovent GMBH
Portable heart-lung machine for bedside use
This article was originally published in Start Up
Executive Summary
Hemovent GMBH has developed a miniaturized extracorporeal membrane oxygenation system for bedside use in intensive care. The start-up says the footprint of its ECMO is just 10% the size of the smallest commercially available heart-lung machine, and the cost of the unit is 95% less than a standard ECMO device.
You may also be interested in...
US Proposed OTC Hearing Aid Rule Inspired Soundly Founder To ‘Make This Process Easier’
In recent interview, CEO Blake Cadwell talked about Soundly’s business model and outlook for hearing aid marketplace after FDA's pending publication of rule aiming to make the devices more accessible. Firm since June has offered online testing and advice for customers about hearing aids best suited for their needs.
Revlon Gains $1.4Bn Financing From Subsidiaries, Appoints Interim CFO Amid Bankruptcy Fallout
Revlon approved for $1.4bn debtor-in-possession financing from BrandCo Lenders, a group of operating subsidiaries formed in capital structure changes which owns much of Revlon’s intellectual property. Firm appoints interim CFO to set course for debt restructuring.
Keeping Track: Enhertu Brings Anti-HER2 Therapy To Lung Cancer; Novaliq Platform Supports Two Dry Eye NDAs
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker.